Tryton Medical announced that it has received CE mark approval for the treatment of left main coronary artery disease. With this approval, Tryton Medical becomes the first company to earn a CE mark for this indication.
“A predictable and safe outcome is essential for the treatment of this high-risk population. The Tryton Side Branch stent provides the necessary control in each step of the procedure,” says Robert Jan van Geuns, of Erasmus MC (Rotterdam, the Netherlands). “With the launch last summer of the Tryton SHORT stent, the expansive range of Tryton stents allows me to definitively treat the vast majority of my left main bifurcation lesions’ cases with a predictable procedure and durable result.”
The Tryton Side Branch Stent is commercially available in Europe and parts of the Middle East, is investigational in the USA, and is not available in Japan.